nodes	percent_of_prediction	percent_of_DWPC	metapath
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0544	0.0549	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0532	0.0537	CbGpPWpGaD
Salbutamol—ADRB1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0464	0.0468	CbGpPWpGaD
Salbutamol—ADRB2—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0454	0.0458	CbGpPWpGaD
Salbutamol—ADRB1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.045	0.0455	CbGpPWpGaD
Salbutamol—ADRB2—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0441	0.0445	CbGpPWpGaD
Salbutamol—ADRB1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.042	0.0423	CbGpPWpGaD
Salbutamol—ADRB2—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.041	0.0414	CbGpPWpGaD
Salbutamol—ADRB1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.039	0.0394	CbGpPWpGaD
Salbutamol—ADRB2—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0381	0.0385	CbGpPWpGaD
Salbutamol—ADRB1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0379	0.0382	CbGpPWpGaD
Salbutamol—ADRB2—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.037	0.0374	CbGpPWpGaD
Salbutamol—ADRB1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0353	0.0356	CbGpPWpGaD
Salbutamol—ADRB2—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0345	0.0348	CbGpPWpGaD
Salbutamol—ADRB1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0294	0.0297	CbGpPWpGaD
Salbutamol—ADRB2—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0287	0.029	CbGpPWpGaD
Salbutamol—ADRB1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0247	0.0249	CbGpPWpGaD
Salbutamol—ADRB2—Arf6 signaling events—MET—Gilles de la Tourette syndrome	0.0244	0.0247	CbGpPWpGaD
Salbutamol—ADRB2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0242	0.0244	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.0202	0.0203	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.0196	0.0198	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.0128	0.0129	CbGpPWpGaD
Salbutamol—Norepinephrine—DRD2—Gilles de la Tourette syndrome	0.00916	1	CrCbGaD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00895	0.00904	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00876	0.00884	CbGpPWpGaD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00869	0.00877	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.0085	0.00858	CbGpPWpGaD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.0081	0.00817	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00792	0.00799	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00767	0.00774	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.0075	0.00757	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00745	0.00752	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00728	0.00735	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00694	0.007	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00679	0.00685	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00584	0.00589	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00571	0.00577	CbGpPWpGaD
Salbutamol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00567	0.00572	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00567	0.00572	CbGpPWpGaD
Salbutamol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00555	0.0056	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00555	0.0056	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00528	0.00533	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00517	0.00522	CbGpPWpGaD
Salbutamol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00486	0.0049	CbGpPWpGaD
Salbutamol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00475	0.0048	CbGpPWpGaD
Salbutamol—ADRB1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.0037	0.00373	CbGpPWpGaD
Salbutamol—ADRB2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00362	0.00365	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.0033	0.00333	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00323	0.00326	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.0032	0.00323	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00313	0.00316	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.003	0.00303	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00299	0.00301	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00293	0.00296	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00292	0.00295	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00291	0.00294	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00285	0.00287	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00271	0.00274	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00265	0.00268	CbGpPWpGaD
Salbutamol—ADRB1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00209	0.00211	CbGpPWpGaD
Salbutamol—ADRB2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00205	0.00206	CbGpPWpGaD
Salbutamol—ADRB1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.0019	0.00192	CbGpPWpGaD
Salbutamol—ADRB2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00186	0.00187	CbGpPWpGaD
Salbutamol—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	0.00179	0.00181	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00177	0.00179	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00173	0.00175	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00172	0.00173	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00168	0.0017	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.0016	0.00162	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00157	0.00158	CbGpPWpGaD
Salbutamol—ADRB1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.00112	0.00113	CbGpPWpGaD
Salbutamol—ADRB2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.0011	0.00111	CbGpPWpGaD
